The effect of Nevazin and vitamin B1 in treatment of chemotherapy-induced neuropathy

Investigating and comparing the therapeutic effect of Nevazin and vitamin B1 in chemotherapy-induced neuropathy in cancer patients undergoing chemotherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230722058878N1

Enrollment

Registered

2023-09-04

Start date

2023-09-21

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: neuropathy. Condition 2: chemotherapy. Drug-induced polyneuropathy Encounter for antineoplastic chemotherapy

Interventions

Intervention 1: Intervention group: Daily prescription of one 150 mg Nevazin tablet produced by Pars Gita Daru Company for three months. Intervention 2: Control group: Daily prescription of one 150 m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All cancer patients who are undergoing chemotherapy

Exclusion criteria

Exclusion criteria: People who are allergic to medicines containing vitamin B use of other drugs effective in improving neuropathy such as Gabapentin, Pregavalin, Duloxetine

Design outcomes

Primary

Measure	Time frame
Severity of neuropathy after chemotherapy. Timepoint: Before and after treatment. Method of measurement: Valk questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Aboozar Mousavi

Iran University of Medical Sciences

aboozar.mousavi28@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026